AfricaRegulatory
African Pharmaceutical Regulatory Intelligence
🇿🇦
Emicizumab in South Africa
4 products registered with SAHPRA — 4 active
| Brand / Product | Reg. No. | Holder | Status | Expires |
|---|---|---|---|---|
| HEMLIBRA 30 mg/ml | 53/30.1/0071 | Roche Products (Pty) Ltd | active | 13 Jan 2030 |
| HEMLIBRA 60 mg/0,4 ml | 53/30.1/0072 | Roche Products (Pty) Ltd | active | 13 Jan 2030 |
| HEMLIBRA 105 mg/0,7 ml | 53/30.1/0073 | Roche Products (Pty) Ltd | active | 13 Jan 2030 |
| HEMLIBRA 150 mg/ ml | 53/30.1/0074 | Roche Products (Pty) Ltd | active | 13 Jan 2030 |
Emicizumab — SAHPRA Registration Details
SAHPRA (South Africa) has 4 registered products containing Emicizumab, of which 4 are currently active. Data is sourced directly from the official SAHPRA drug register and refreshed daily.
Track Emicizumab registration expiry dates, monitor competitor approvals, and receive alerts when registration status changes. Create a free account to set up portfolio monitoring.